We are dedicated to translating state-of-the-art science into novel medicines for the treatment of diseases that pose great challenges to patients, their physicians and their families. Our strength derives from our focus on a handful of devastating but related diseases, the skills and experience of our team and the commitment of our investors.
Basic biological discoveries that truly illuminate the ontogenic paths cells take to a disease state inspire us because these insights suggest treatment strategies that are often novel and offer the prospect of superior clinical outcomes. In this era, the genomic age of medical science, the underlying genetic and gene regulatory aberrations of many conditions have been revealed but patients have not yet been the beneficiaries. Our goal is to transition those insights into medicines.
Our name, Imago, (pron. i-mắ-go), invokes the final and fully developed stage of an insect after its metamorphosis. In this process of growth and development, the imago refers to the fully formed adult, one that has completed its transformation and, for a butterfly, has taken flight. In our view, the full maturation of a scientific idea or observation in medical research is when new treatments prove their worth in clinical studies. To patients, anything less is to miss the mark.
The first development program at Imago BioSciences to enter the clinic targets an enzyme essential for maintaining the disease state of a family of bone marrow disorders that includes myeloproliferative neoplasms (MPNs) as well as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These diseases are life-threatening and have proven challenging to manage and even more difficult to cure.